Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936597 | 0.86 | ACHE (0.39) | P2RX3ACHEMRGPRX4ALDH1A1CYP3A4 | |
| SCHEMBL12648042 | 0.85 | NAAA (0.43) | P2RX3KCNQ3KCNQ2TRPV3ALDH1A1 | |
| SCHEMBL20128041 | 0.84 | MRGPRX4 (0.39) | ACHEMRGPRX4ALDH1A1CYP3A4MEN1 | |
| SCHEMBL879131 | 0.83 | ACHE (0.40) | P2RX3ACHEIDO1TDO2CSNK2A1 | |
| SCHEMBL10052629 | 0.83 | ALDH1A1 (0.49) | ACHEMRGPRX4ALDH1A1CYP3A4MEN1 | |
| SCHEMBL171317 | 0.81 | MRGPRX4 (0.38) | P2RX3ACHEMRGPRX4DHODH | |
| SCHEMBL5745812 | 0.81 | MEN1 (0.50) | P2RX3KCNQ3KCNQ2CSNK2A1TRPV3 | |
| SCHEMBL12313570 | 0.80 | ACHE (0.50) | ACHEIDO1TDO2CSNK2A1ALDH1A1 | |
| SCHEMBL15672721 | 0.80 | MRGPRX4 (0.40) | P2RX3ACHEMRGPRX4TRPV3ALDH1A1 | |
| SCHEMBL15672725 | 0.80 | MRGPRX4 (0.40) | P2RX3ACHEMRGPRX4TRPV3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090042954-A1 | 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | P2RX3 1004/4885ACHE 2653/4885KCNQ3 4115/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | P2RX3 2366/4885ACHE 4655/4885KCNQ3 4265/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | P2RX3 2424/4885ACHE 4413/4885KCNQ3 4844/4885 |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | NR4A1, NR0B2, NR0B1 | P2RX3 556/4885ACHE 2160/4885KCNQ3 1677/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | P2RX3 2096/4885ACHE 4354/4885KCNQ3 4036/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | P2RX3 1431/4885ACHE 3515/4885KCNQ3 3621/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | P2RX3 3288/4885ACHE 4675/4885KCNQ3 1617/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | P2RX3 1735/4885ACHE 3993/4885KCNQ3 3872/4885 |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, PIK3CB | P2RX3 2667/4885ACHE 3274/4885KCNQ3 4098/4885 |
| US-20090042954-A1 | 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists | S1PR1, S1PR3, S1PR5 | P2RX3 235/4885ACHE 4190/4885KCNQ3 3631/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | P2RX3 4834/4885ACHE 4853/4885KCNQ3 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.